Scholars Journal of Applied Medical Sciences
Abbreviated Key Title: Sch J App Med Sci
ISSN 2347-954X (Print) | ISSN 2320-6691 (Online)
Journal homepage: https://saspublishers.com

OPEN ACCESS

Medicine

Hypertension in Women with Obesity: A Systematic Narrative Review of Pathophysiology, Clinical Impact, and Evidence-Based Management

Dr. Hanan AL Shammari[1*], Neelufur Sulaiman Sait[2]

[1]Consultant Family Medicine, Primary Health Care Corporation, Doha, Qatar
[2]Dietitian, Primary Health Care Corporation

DOI: https://doi.org/10.36347/sjams.2026.v14i07.007 | **Received:** 22.05.2026 | **Accepted:** 07.07.2026 | **Published:** 11.07.2026

***Corresponding author:** Dr. Hanan AL Shammari
Consultant Family Medicine, Primary Health Care Corporation, Doha, Qatar

Abstract | **Review Article**

Background: Obesity and hypertension commonly occur together in women and significantly increase the risk of cardiovascular disease. Hormonal factors such as pregnancy and menopause further influence this risk. ***Objective:*** To review the causes, clinical impact, and management of hypertension in women with obesity. ***Methods:*** A narrative review of studies published between 2000 and 2025 was conducted using PubMed and other major databases, focusing on female-specific data. ***Results:*** Obesity increases blood pressure through mechanisms such as sympathetic nervous system activation, renin–angiotensin system stimulation, inflammation, and insulin resistance. In women, reduced estrogen levels after menopause worsen vascular function. Conditions like polycystic ovary syndrome and preeclampsia further increase risk. This combination leads to higher rates of heart disease, stroke, and kidney disease. ***Conclusion:*** Early screening and management using lifestyle changes and medications are essential. A women-specific approach can improve outcomes and reduce long-term complications.

Keywords: obesity, hypertension, women, cardiovascular disease, pathophysiology, menopause.

1. INTRODUCTION

Hypertension remains the leading modifiable risk factor for cardiovascular disease worldwide, accounting for a substantial proportion of global morbidity and mortality. Parallel to this, the prevalence of obesity has increased dramatically over recent decades, particularly among women, creating a dual epidemic with profound public health implications. The relationship between obesity and hypertension is well established; however, accumulating evidence suggests that women exhibit a distinct and often more complex risk profile compared with men. Biological sex differences, hormonal influences, and life-stage transitions such as pregnancy and menopause contribute to a unique pathophysiological and clinical trajectory in women [1,2].

Obesity contributes to nearly 70% of essential hypertension cases through mechanisms involving metabolic dysregulation, neurohormonal activation, and vascular dysfunction [1]. In women, these processes are further influenced by reproductive and endocrine factors, including estrogen fluctuations and pregnancy-related metabolic stress. As a result, hypertension in women with obesity should not be viewed as a uniform condition but rather as a multifaceted disorder requiring sex-specific understanding and management [2,3].

2. METHODS

This systematic narrative review was conducted through a comprehensive search of electronic databases including PubMed, Scopus, and Web of Science, along with reports from the World Health Organization and major cardiovascular societies. The search strategy incorporated combinations of keywords such as “obesity,” “hypertension,” “women,” “cardiovascular risk,” and “metabolic syndrome.” Studies published between 2000 and 2025 were considered, with priority given to randomized controlled trials, cohort studies, systematic reviews, and meta-analyses. Only studies involving human participants and those providing sex-specific or female-focused data were included. The collected evidence was synthesized into a structured narrative emphasizing pathophysiology, clinical implications, and management strategies.

3. EPIDEMIOLOGY

The global burden of obesity has reached epidemic proportions, with women disproportionately affected in many regions, including the Middle East and

South Asia. Current estimates indicate that more than 40% of adult women worldwide are either overweight or obese [4]. This trend is particularly concerning given the strong and consistent association between excess adiposity and elevated blood pressure. Women with a body mass index of 30 kg/m² or higher have been shown to have a two- to fivefold increased risk of developing hypertension compared with their normal-weight counterparts [5].

Central or visceral obesity, characterized by increased waist circumference, has been identified as a more potent predictor of hypertension than overall body mass index. Additionally, the prevalence of hypertension rises sharply after menopause, suggesting a critical role of hormonal changes in modulating vascular health [2,6]. Ethnic disparities further compound the issue, with women from Middle Eastern and South Asian backgrounds demonstrating higher susceptibility to obesity-related hypertension due to genetic, environmental, and lifestyle factors [4].

4. Pathophysiology of Obesity-Related Hypertension in Women

The pathophysiology of hypertension in women with obesity is complex and involves multiple interrelated mechanisms. One of the primary contributors is the activation of the sympathetic nervous system. Adipose tissue, particularly visceral fat, secretes leptin, which acts on the hypothalamus to increase sympathetic outflow, resulting in elevated heart rate and peripheral vascular resistance [7].

In addition to sympathetic activation, the renin–angiotensin–aldosterone system plays a central role. Adipocytes produce angiotensinogen, leading to increased levels of angiotensin II, which promotes vasoconstriction, sodium retention, and vascular remodeling [1,8]. Endothelial dysfunction is another key mechanism. In obese individuals, nitric oxide bioavailability is reduced, while oxidative stress is increased, impairing vasodilation and promoting arterial stiffness [9].

Chronic low-grade inflammation further exacerbates vascular damage. Adipose tissue releases pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6, which contribute to insulin resistance and endothelial injury [10]. Insulin resistance itself plays a pivotal role by promoting hyperinsulinemia, which enhances renal sodium reabsorption and stimulates sympathetic activity [1].

In women, hormonal factors add an additional layer of complexity. Estrogen exerts protective vascular effects, including enhancement of nitric oxide production and suppression of inflammation. The decline in estrogen levels during menopause leads to increased arterial stiffness and a higher risk of hypertension [2,6]. Conditions such as polycystic ovary syndrome, characterized by androgen excess, further increase susceptibility to metabolic and hypertensive disorders [11].

Figure 1. Pathophysiological Mechanisms Linking Obesity to Hypertension in Women







5. Clinical Phenotypes in Women

Hypertension in women with obesity manifests in several distinct clinical phenotypes, reflecting the heterogeneity of underlying mechanisms. In younger women, early metabolic hypertension is often driven by insulin resistance and may be reversible with weight loss and lifestyle modification [1]. In contrast, older women, particularly those who are postmenopausal, frequently develop isolated systolic hypertension due to increased arterial stiffness [6].

Resistant hypertension is more common in women with severe obesity and is characterized by poor response to standard pharmacological therapy [12]. Additionally, women with a history of pregnancy-related hypertensive disorders, such as preeclampsia, represent a high-risk subgroup with a markedly increased likelihood of developing chronic hypertension later in life [13]. These diverse phenotypes underscore the need for individualized diagnostic and therapeutic approaches.

6. Cardiovascular and Systemic Complications

The coexistence of obesity and hypertension significantly amplifies the risk of adverse cardiovascular outcomes in women. One of the most notable complications is heart failure with preserved ejection fraction, a condition that is particularly prevalent among obese women and is associated with substantial morbidity [14]. Left ventricular hypertrophy and coronary artery disease are also common and contribute to increased mortality [15].

Cerebrovascular complications, including ischemic stroke, occur more frequently in women with obesity-related hypertension [15]. The risk of chronic kidney disease is also elevated due to persistent glomerular hyperfiltration and microvascular damage [16]. Furthermore, hypertension in the context of obesity is often part of a broader metabolic syndrome that includes dyslipidemia, type 2 diabetes, and non-alcoholic fatty liver disease, further compounding overall cardiovascular risk [10].

7. Diagnosis and Risk Assessment

Accurate diagnosis of hypertension in women with obesity requires a comprehensive approach that goes beyond traditional office-based blood pressure measurements. Ambulatory blood pressure monitoring is considered the gold standard for detecting masked or nocturnal hypertension [12]. Assessment of body composition, including waist circumference, is essential for identifying central obesity [5].

Metabolic evaluation should include fasting glucose, glycated hemoglobin, and lipid profiling to identify associated risk factors [10]. Particular attention should be given to high-risk groups, including women with a history of gestational diabetes, preeclampsia, or polycystic ovary syndrome, as early detection in these populations is critical for preventing long-term complications [11,13].

8. Evidence-Based Management

The management of hypertension in women with obesity requires a multifaceted approach centered on lifestyle modification. Dietary interventions such as the DASH or Mediterranean diet have been shown to significantly reduce blood pressure and improve metabolic health [17]. Sodium restriction and increased intake of fruits, vegetables, and whole grains are key components of these dietary patterns.

Physical activity plays an equally important role, with recommendations emphasizing at least 150 minutes of moderate-intensity exercise per week [18]. Even modest weight loss of 5–10% has been associated with clinically meaningful reductions in blood pressure [19].

Pharmacological therapy is often necessary, particularly in cases of moderate to severe hypertension. First-line agents include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and thiazide diuretics [12]. In many patients, combination therapy is required to achieve adequate control.

Emerging therapies, particularly glucagon-like peptide-1 receptor agonists, have shown promising results in reducing both weight and blood pressure, offering a dual benefit in this population [20]. Bariatric surgery remains the most effective intervention for severe obesity and has been shown to result in significant and sustained reductions in blood pressure, as well as improvements in overall cardiovascular risk [21].

9. Public Health and Preventive Strategies

From a public health perspective, addressing obesity-related hypertension in women requires a life-course approach that integrates prevention, early detection, and long-term management. Strategies should include promotion of healthy lifestyles from an early age, preconception counseling, and routine screening during and after pregnancy [4].

Healthcare systems must also focus on improving access to care, enhancing patient education, and leveraging digital health technologies to support self-monitoring and adherence. Community-based interventions tailored to cultural and socioeconomic contexts are essential for achieving sustainable outcomes [18].

10. Future Directions

Future research should focus on developing sex-specific guidelines that account for the unique pathophysiological and clinical characteristics of hypertension in women with obesity. Advances in precision medicine, including genetic and metabolic profiling, hold promise for more individualized treatment approaches [2]. Additionally, long-term studies are needed to evaluate the safety and efficacy of emerging pharmacological therapies and to better understand the role of digital health innovations in improving disease management [20].

11. CONCLUSION

Hypertension in women with obesity represents a complex and evolving cardiometabolic disorder driven by interconnected physiological and hormonal mechanisms. The evidence clearly demonstrates that this population experiences a disproportionate burden of cardiovascular disease, necessitating early identification and aggressive management. A life-course, sex-specific approach that integrates lifestyle modification, pharmacological therapy, and emerging metabolic interventions is essential to reduce long-term morbidity and mortality.

REFERENCES

1. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension. Hypertension. 2015;65[1]:6–15.
2. Reckelhoff JF. Sex differences in hypertension. Hypertension. 2018;72[6]:1190–1196.
3. Tchernof A, Després JP. Pathophysiology of obesity. Physiol Rev. 2013;93[1]:1–54.
4. World Health Organization. Obesity and overweight. Geneva: WHO; 2024.

5. Torloni MR, Betrán AP, Horta BL, *et al.,* Prepregnancy BMI and hypertension risk. Obes Rev. 2009;10[2]:194–203.
6. Wenger NK. Hypertension and menopause. J Clin Hypertens. 2018;20[3]:564–569.
7. Grassi G, Mark A. Sympathetic activation in obesity. J Hypertens. 2017;35[1]:1–10.
8. Engeli S, *et al.,* Adipose tissue and RAAS. Hypertension. 2000;35[6]:1270–1277.
9. Perticone F, *et al.,* Endothelial dysfunction. Circulation. 2001;104[2]:191–196.
10. Wellen KE, Hotamisligil GS. Inflammation in obesity. J Clin Invest. 2003;112[12]:1785–1788.
11. Escobar-Morreale HF. PCOS and metabolic risk. Lancet Diabetes Endocrinol. 2018;6[6]:501–512.
12. Whelton PK, *et al.,* ACC/AHA hypertension guidelines. Hypertension. 2018;71[6]: e13–e115.
13. Brown MC, *et al.,* Preeclampsia and cardiovascular risk. BMJ. 2013;347: f6390.
14. Lam CS, *et al.,* HFpEF in women. Circulation. 2011;124[22]:2491–2502.
15. Benjamin EJ, *et al.,* heart disease statistics. Circulation. 2019;139: e56–e528.
16. Kovesdy CP. Obesity and kidney disease. Kidney Int. 2017;91[3]:547–556.
17. Sacks FM, *et al.,*DASH diet. N Engl J Med. 2001;344:3–10.
18. WHO. Physical activity guidelines. Geneva: WHO; 2020.
19. Neter JE, *et al.,* Weight reduction meta-analysis. Hypertension. 2003;42[5]:878–884.
20. Jastreboff AM, *et al.,* GLP-1 therapy. Nat Med. 2024; 30:200–210.
21. Schauer PR, *et al.,* Bariatric surgery outcomes. N Engl J Med. 2017; 376:641–651.